Abstract 532P
Background
Immune checkpoint inhibitors (ICIs) have come to be used for the treatment of the patients with malignant pleural mesothelioma (MPM). Although modified RECIST (mRECIST) criteria is the standard method to evaluate the antitumor efficacy of ICIs, it is sometimes difficult to distinguish progressive disease from pseudoprogression (PsPD). While serum soluble mesothelin related peptide (SMRP) is commonly known as a specific tumor marker of MPM, the significance of SMRP levels in determining the efficacy of ICI treatment has not been established.
Methods
We investigated the relationship between changes of serum SMRP levels and treatment response in MPM patients treated with ipilimumab plus nivolumab combination therapy at our hospital between June 2021 and January 2023.
Results
Twenty-eight patients were included in the study. Median age was 75 years (59-85). The number of histological subtypes of epithelioid, sarcomatoid, biphasic and desmoplastic were 18, 6, 3 and 1, respectively. Treatment response was evaluated by mRECIST. The number of patients who achieved partial response (PR), stable disease (SD) and progressive disease (PD) were 9, 16 and 3, respectively. Among 25 patients with PR and SD, PsPD was observed in 5 patients (PR/SD: 3/2). The median serum SMRP before treatment in all patients was 0.90 nmol/L (0.4 - 16.9)., and the change from baseline at the time of first evaluation was +0.1 nmol/L (-4.5 - +24.5), The median change of serum SMRP level from baseline in patients with PR, SD, PsPD and PD was 0.0 nmol/L (-1.0 - +1.4), +0.1 nmol/L (-4.5 - +4.5), +0.2 nmol/L (-0.9 - +0.9) and +19.5 nmol/L (+0.1 - +24.5), respectively. These results indicated that serum SMRP level in patients with PD already tended to increase at the time of first evaluation.
Conclusions
Our results suggested that changes in serum SMRP levels was useful in determining the efficacy of ICI treatment. We are planning to accumulate more cases in the future for further investigation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract